Diabetic autonomic neuropathy

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 176-193

  Kamenov, Zdravko A ^a   Traykov, Latchezar D ^a  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CAFFEINE; CISAPRIDE; CLONIDINE; CODEINE; DESIPRAMINE; DOMPERIDONE; EPHEDRINE; ERYTHROPOIETIN; FLUDROCORTISONE; FLUOXETINE; IMIPRAMINE; LOPERAMIDE; METOCLOPRAMIDE; MIDODRINE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; PSEUDOEPHEDRINE; PYRIDOSTIGMINE; SILDENAFIL; SOMATOSTATIN DERIVATIVE; TADALAFIL; TESTOSTERONE; UNINDEXED DRUG; VARDENAFIL; VASOPRESSIN DERIVATIVE; YOHIMBINE;

AMPUTATION; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; AUTONOMIC NEUROPATHY; CARDIOVASCULAR AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CONSTIPATION; DIABETIC FOOT; DIABETIC NEUROPATHY; DIAGNOSTIC TEST; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ERECTILE DYSFUNCTION; GASTROINTESTINAL AUTONOMIC NEUROPATHY; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HYPOACTIVE SEXUAL DESIRE DISORDER; HYPOGLYCEMIA; PUPIL DISEASE; RETROGRADE EJACULATION; STOMACH PARESIS; SWEAT GLAND DISEASE; ULCER; UROGENITAL TRACT DISEASE; AUTONOMIC NERVOUS SYSTEM; CLASSIFICATION; HUMAN; PATHOPHYSIOLOGY; REVIEW;

AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETIC NEUROPATHIES; HUMANS;

MLCS; MLOWN;

EID: 84874543713     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_15     Document Type: Article

References (109)

1. Boulton AJ, Malik RA, Arezzo JC et al. Diabetic somatic neuropathies. Diabetes Care 2004; 27(6): 1458-1486.
2. Low PA, Benrud-Larson LM, Sletten DM et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27:2942-2947.
3. Boulton AJ, Vinik AI, Arezzo JC et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28(4):956-962.
4. Pfeifer MA, Weinberg CR, Cook DL et al. Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984; 7:447-453.
5. Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26:1553-1579.
6. Scott WA. Assessment of the autonomic nervous system. In: Moss and Adams heart disease in infants and adolescents including the fetus and young adult. Baltimore (et.) Williams and Wilkins 1995; 172-181.
7. Jaradeh SS, Prieto TE. Evaluation of the autonomic nervous system. Phys Med Rehabil Clin N Am 2003; 14:287-305.
8. Zygmunt A, Stanczyk J. Methods of evaluation of autonomic nervous system function. Arch Med Sci 2010; 6(1):11-18.
9. American Diabetes Association, American Academy of Neurology: Report and recommendations of the San Antonio Conference on Diabetic Neuropathy (Consensus Statement). Diabetes Care 1988; 11:592-597.
10. Thomas PK. Classification of the diabetic neuropathies. In: Gries FA, Cameron NE, Low PA et al, (eds.). Textbook of Diabetic Neuropathy. Stuttgart: Thieme 2003:175-177.
11. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997; 46(Suppl 2):S54-S57.
12. Tesfaye S, Boulton AJ, Dyck PJ et al. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33(10):2285-2293.
13. Valensi P, Pariès J, Attali JR. French Group for Research and Study of Diabetic Neuropathy. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications-the French multicenter study. Metabolism 2003; 52:815-820.
14. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115:387-397.
15. Ewing DJ, Martyn CN, Young RJ et al. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8(5):491-498.
16. Ewing DJ. Autonomic neuropathy. In: Pickup JC, Williams G (eds.). Chronic complications of diabetes. Blackwell Scientific Publications Oxford 1994:124-136.
17. American Academy of Neurology. Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 46:873-880.
18. England JD, Gronseth GS, Franklin G et al. American Academy of Neurology. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review): report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72:177-184.
19. Langen KJ, Ziegler D, Weise F et al. Evaluation of QT interval length, QT dispersion and myocardial m-iodobenzylguanidine uptake in insulin-dependent diabetic patients with and without autonomic neuropathy. Clin Sci Colch 1997; 93:325-333.
20. Ziegler D, Langen K, Weise F. Contribution de l'imagerie scintigraphique a l'etude de l'innervation sumpathique. In: Valensi P, Feuvray, D, Sach R-N, eds. Coeur et Diabete. Paris, France: Editions Frison-Roche 1999:443-455.
21. Ziegler D, Weise F, Langen KJ et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123 I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998; 41:443-451.
22. Stevens M, Raffel D, Allman KC et al. Cardiac sympathetic dysinnervation in diabetes implications for enhanced cardiovascular risk. Circulation 1998; 98:961-968.
23. Stevens MJ, Dayanikli F, Raffel DM et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol 1998; 31:1575-1584.
24. Pop-Busui R, Kirkwood I, Schmid H et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 2004; 44:2368-2374.
25. Stevens M. Cardiovascular Autonomic Neuropathy. In: Veves A, Malik R (eds.). Diabetic Neuropathy: Clinical Management, Second Edition, Totowa, New Jersey: Humana Press Inc. 2007:389-412.
26. Bytzer P, Talley NJ, Leemon M et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 2001; 161(16): 1989-1996.
27. Chandran M, Chu NV, Edelman SV. Gastrointestinal disturbances in diabetes. Curr Diab Rep 2003; 3(1):43-48.
28. Perusicova J. Gastrointestinal complications in diabetes mellitus. Vnitr Lek 2004; 50(5):338-343.
29. Rayner CK, Horowitz M. Gastrointestinal motility and glycemic control in diabetes: the chicken and the egg revisited? J Clin Invest 2006; 116:299-302.
30. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127:1592-1622.
31. Nishida T, Tsuji S, Tsujii M et al. Gastroesophageal reflux disease related to diabetes: Analysis of 241 cases with type 2 diabetes mellitus. J Gastroenterol Hepatol 2004; 19(3):258-265.
32. Jones KL, Russo A, Stevens JE et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001;24:1264-1269.
33. Malagelada J-R. Gastrointestinal Syndromes Due to Diabetes Mellitus. In: Veves A, Malik R (eds.). Diabetic Neuropathy: Clinical Management, Second Edition, Totowa, New Jersey: Humana Press Inc. 2007; 433-451.
34. De Block CE, De Leeuw IH, Pelckmans PA et al. Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. Diabetes Care 2002; 25(5):912-917.
35. Wald A. Incontinence and anorectal dysfunction in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995; 7(8):737-739.
36. Horowitz M, Maddox AF, Wishart JM et al. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18:229-234.
37. Stanciu GO. Gastroparesis and its management. Rev Med Chir Soc Med Nat Iasi 2001;105(3):451-456.
38. Gentilcore D, O'Donovan D, Jones KL et al. Nutrition therapy for diabetic gastroparesis. Curr Diab Rep 2003;3(5):418-426.
39. Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol 2003; 98(2):264-271.
40. Forster J, Sarosiek I, Delcore R et al. Gastric pacing is a new surgical treatment for gastroparesis. Am J Surg 2001; 182(6):676-681.
41. Abell T, Lou J, Tabbaa M et al. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and longterm follow-up. JPEN J Parenter Enteral Nutr 2003; 27(4):277-281.
42. Farthing M. Effective treatment of diabetic diarrhea with a somatostatin analogue. Gut 1992; 33:1578-1580.
43. Nakabayashi H, Fujii S, Milwa U et al. Marked improvement of diabetic diarrhea with the somatostatin analogue octreotide. Arch Int Med 1994; 154:1863-1867.
44. Meyer C, O'Neal DN, Connell W et al. Octeotride treatment of severe diabetic diarrhoea. Int Med J 2003; 33:617-624.
45. Cooper ZR, Rose S. Fecal incontinence: a clinical approach. Mt Sinai J Med 2000; 67(2):96-105.
46. Fedele D, Coscelli C, Santeusanio F et al. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care 1998; 21(11): 1973-1977.
47. Saenz de Tejada I, Goldstein I, Krane RJ. Local control of penile erection. Nerves, smooth muscle and endothelium. Urol Clin North Am 1988; 15(1):9-15.
48. Nofzinger EA. Sexual Dysfunction in Patients with Diabetes Mellitus: The Role of a "Central" Neuropathy. Semin Clin Neuropsychiatry 1997; 2(1):31-39.
49. Kamenov Z, Christov V, Yankova T. Erectile dysfunction in diabetic men-linked more to microangiopathic complications and neuropathy than to macroangiopathic disturbances. Journal of Men's Health and Gender 2007; 4(1):64-73.
50. Mulligan T, Frick MF, Zuraw QC et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60(7):762-769.
51. Dhindsa S, Prabhakar S, Sethi M et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89:5462-5468.
52. Corrales JJ, Burgo RM, Garca-Berrocal B et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004; 53:666-672.
53. Rosen RC, Riley A, Wagner G et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile function. Urology 1997; 49:822-830.
54. Costabile RA. Optimizing treatment for diabetes mellitus induced erectile dysfunction. J Urol 2003; 170(2 Pt 2):S35-S38.
55. Snow JK. Erectile dysfunction in patients with diabetes mellitus-advances in treatment with phosphodiesterase type 5 inhibitors. Br J Diabetes Vase Dis 2002; 2:282-287.
56. Kamenov Z. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. JSM 2011; 8(3):851-864.
57. Colpi G, Weidner W, Jungwirth A et al. EAU Working Party on Male Infertility. EAU guidelines on ejaculatory dysfunction. Eur Urol 2004; 46(5):555-558.
58. McMahon C, Waldinger M, Rowland D et al. Ejaculatory disorders. In: Standard practice in Sexual medicine. Eds. H. Porst, J. Buvat, Blackwell Publishing 2006; 315-319.
59. Ralph DJ, Wylie KR. Ejaculatory disorders and sexual function. BJU Int 2005; 95(9): 1181-1186.
60. Kamischke A, Nieschlag E. Treatment of retrograde ejaculation and anejaculation. Hum Reprod Update 1999; 5(5):448-474.
61. Jimenez C, Grizard G, Pouly JL et al. Birth after combination of cryopreservation of sperm recovered from urine and intracytoplasmic sperm injection in a case of complete retrograde ejaculation. Fertil Steril 1997; 68(3):542-544.
62. Abrahams JI, Solish GI, Boorjian P et al. The surgical correction of retrograde ejaculation. J Urol 1975; 114(6):888-890.
63. Ramadan AE, el-Demiry MI. Surgical correction of post-operative retrograde ejaculation. Br J Urol 1985; 57(4):458-461.
64. Middleton RG, Urry RL. The Young-Dees operation for the correction of retrograde ejaculation. J Urol 1986; 136(6): 1208-1209.
65. Enzlin P, Mathieu C, Vanderschueren D et al. Diabetes mellitus and female sexuality: a review of 25 years' research. Diabet Med 1998; 15:809-815.
66. Lindau S, Tang H, Gomero A et al. Sexuality among middle-aged and older adults with diagnosed and undiagnosed diabetes. A national, population-based study. Diabetes Care 2010; 33(10):2202-2210.
67. Doruk H, Akbay E, Cay an S et al. Effect of diabetes mellitus on female sexual function and risk factors. Arch Androl 2005; 51(1):1-6.
68. Wallner LP, Sarma AV, Kim C. Sexual functioning among women with and without diabetes in the Boston Area Community Health Study. J Sex Med 2010; 7(2 Pt 2):881-887.
69. Enzlin P, Rosen R, Wiegel M et al. and the DCCT/EDIC Research Group. Sexual dysfunction in women with type 1 diabetes long-term findings from the DCCT/EDIC study cohort. Diabetes Care 2009; 32(5): 780-785.
70. Ziegler D, Stief C. Genitourinary Complications. In: Veves A, Malik R, eds. Diabetic Neuropathy: Clinical Management, Second Edition, Totowa, New Jersey: Humana Press Inc. 2007; 453-472.
71. Jovanovic L. Sex and the woman with diabetes: desire versus dysfunction. IDF Bull 1998; 43:23-28.
72. Dennerstein L, Alexander J, Graciotin A. Sexual desire disorders in women. In: H. Porst, J. Buva, eds. Standard practice in Sexual medicine. Blachwell Publishing 2006; 315-319.
73. Buster JE, Kingsberg SA, Aguirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105:944-952.
74. Davis SR, van der Mooren MJ, van Lunsen RH et al. Efficacy and safely of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006; 13:387-396.
75. Shifren JL, Davis SR, Moreau M et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause 2006; 13(5):770-779.
76. Wierman ME, Basson R, Davis SR et al. Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline J Clin Endocrinol and Metab 2006; 91(10):3697-3716.
77. Traish A, Guay A. Spark Rand the Testosterone Therapy in Women Study Group. Are the Endocrine Society's Clinical Practice Guidelines on Androgen Therapy in Women Misguided? A Commentary. J Sex Med 2007; 4:1223-1235.
78. Low PA. Sudomotor function. In: Textbook of Diabetic Neuropathy. Eds.: FA Gries, PA Low, NE Cameron, D Ziegler. Publ. G. Thieme Verlag 2003; 274-278.
79. Guttmann L. The management of the quinizarin sweat test (QST). Postgrad Med J 1947; 23:353-366.
80. Fealey RO. The thermoregulatory sweat test. In: Low PA (ed.) Clinical autonomic disorders: evaluation and management. Boston: Little, Brown and Company 1993:217-229.
81. Lang E, Spitzer A, Claus O et al. Stimulation of sudomotor axon reflex mechanism by carbachol in healthy subjects and patients suffering from diabetic polyneuropathy. Acta Neurol Scand 1995; 91:251-254.
82. Shahani BT, Halperin JJ, Boulu P et al. Sympathetic skin response: a method of assessing unmyelinated axon dysfunction in peripheral neuropathies. J Neurol Neurosurg Psychiatry 1984; 47:536-542.
83. Low VA, Sandroni P, Fealey RD et al. Detection of small-fiber neuropathy by sudomotor testing. Muscle Nerve 2006; 34(1):57-61.
84. Papanas N, Papatheodorou K, Christakidis D et al. Evaluation of a new indicator test for sudomotor function (neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinology Diabetes 2005; 113:1-4.
85. Schnell O, Mueler M, Standi E. Early detection of changes in the feet of diabetic patients with indicator test Neuropad®. Diabetes, Metabolism and the Heart 2008; 17(3):203-210.
86. Liatis S, Marinou K, Tentolouris N et al. Usefulness of a new indicator test for the diagnosis of peripheral and autonomic neuropathy in patients with diabetes mellitus. Diabet Med 2007; 24(12): 1375-1380.
87. Quattrini C, Jeziorska M, Tavakoli M et al. The Neuropad test: a visual indicator test for human diabetic neuropathy. Diabetologia 2008; 51(6):1046-1050.
88. Tentolouris N, Achtsidis V, Marinou K et al. Evaluation of the self-administered indicator plaster neuropad for the diagnosis of neuropathy in diabetes. Diabetes Care 2008; 31(2):236-237.
89. Kamenov Z, Petrova J, Christov V. Diagnosis of diabetic neuropathy and risk determination using simple somatic and a new autonomic (Neuropad®) tests in the clinical practice. Exp Clin Endocrinol Diabetes 2010; 118(4):226-233.
90. Papanas N, Papatheodorou K, Papazoglou D et al. Reproducibility of the new indicator test for sudomotor function (Neuropad) in patients with type 2 diabetes mellitus: short communication. Exp Clin Endocrinol Diabetes 2005; 113(10):577-581.
91. Beerens AJ, Snow GB. Botulinum toxin A in the treatment of patients with Frey syndrome. Br J Surg 2002; 89:116-119.
92. Donovan CM, Hamilton-Wessler M, Halter JB et al. Primacy of liver glucosensors in the sympathetic response to progressive hypoglycemia. Proc Natl Acad Sci U S A 1994; 91(7):2863-2867.
93. Borg WP, During MJ, Sherwin RS et al. Ventromedial hypothalamic lesions in rats suppress counter regulatory responses to hypoglycemia. J Clin Invest 1994; 93(4): 1677-1682.
94. Borg WP, Sherwin RS, During MJ et al. Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes 1995; 44(2): 180-184.
95. Ritter S, Llewellyn-Smith I, Dinh TT. Subgroups of hindbrain catecholamine neurons are selectively activated by 2-deoxy-D-glucose induced metabolic challenge. Brain Res 1998; 805(1-2):41-54.
96. Freeman R. Hypoglucemia and the autonomic nervous system. In: Veves A., Malik R (eds.). Diabetic Neuropathy: Clinical Management, Second Edition, Totowa, New Jersey: Humana Press Inc 2007:379-388.
97. Cryer PE. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2004; 350(22):2272-2279.
98. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26(6): 1902-1912.
99. Diedrich L, Sandoval D, Davis SN. Hypoglycemia associated autonomic failure. Clin Auton Res 2002; 12(5):358-365.
100. Fanelli CG, Epifano L, Rambotti AM et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42(11):1683-1689.
101. Davis M, Mellman M, Friedman S et al. Recovery of epinephrine response but not hypoglycemic symptom threshold after intensive therapy in type 1 diabetes. Am J Med 1994; 97(6):535-542.
102. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counter regulation, in IDDM. Diabetes 1994; 43(12): 1426-1434.
103. Lingenfelser T, Buettner UW, Uhl H et al. Recovery of hypoglycaemia-associated compromised cerebral function after a short interval of euglycaemia in insulin-dependent diabetic patients. Electroencephalogr Clin Neurophysiol 1994; 92(3): 196-203.
104. Cranston I, Lomas J, Maran A et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344(8918):283-287.
105. Fanelli C, Pampanelli S, Epifano L et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994; 37(12): 1265-1276.
106. Buse JB, Bigger JT, Byington RP et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99:21i-33i.
107. Gerstein HC, Miller ME, Byington RP et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24):2545-2559.
108. Duckworth W, Abraira C, Moritz T et al. Intensive glucose control and complications in American veterans with type 2 diabetes. N Engl J Med 2009; 360:129-139.
109. Abraira C, Duckworth WC, Moritz T. VADT Group. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab 2009; 11:150-156.